Search Blog
Categories
July 2017
M T W T F S S
« Jun   Aug »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Tags

INVESTOR ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline – July 11, 2017

ACCESSWIRE

By Bronstein, Gewirtz and Grossman, LLC

NEW YORK, NY / ACCESSWIRE / July 3, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Akari Therapeutics Plc (“Akari” or the “Company”) (NASDAQ: AKTX) and certain of its officers, on behalf of shareholders who purchased Akari securities between March 30, 2017 and May 11, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aktx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and specifically that: (1) Dr. Gur Roshwalb (“Roshwalb”), Akari’s Chief Executive Officer (“CEO”), and possibly others, caused false information about Akari to be published, including but not limited to, false information regarding the Phase 2 PNH trial of Coversin; (2) Akari lacked sufficient controls and protections to prevent such behavior; and (3) consequently, Akari’s financial statements were materially false and misleading at all relevant times.

According to the complaint, following an announcement made on May 11, 2017 that Akari’s CEO, Roshwalb was placed on administrative leave while the Board of Directors investigates the involvement of Akari personnel related to with a report issued on April 26, 2017, Akari stock dropped significantly.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/aktx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Akari you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 465182